US FTC Sues to Block Covetrus–MWI Animal Health’s US$3.5 Billion Merger

US Federal Trade Commission, supported by 13 state attorneys general, has filed a federal lawsuit seeking to prevent Covetrus from acquiring MWI Animal Health from Cencora. The regulator argues that the transaction would eliminate a major source of competition in veterinary distribution, potentially increasing procurement costs for veterinary clinics, corporate veterinary groups and, ultimately, pet owners. Covetrus disputes the regulator’s market definition, pointing to digital marketplaces, direct manufacturer sales and a wider network of distributors as evidence that competition remains substantial.

Published: 14 November 2026 | Sector: Animal Health, M&A and Antitrust Regulation | Geography: United States

A US$3.5 billion transaction faces a major regulatory challenge

The US veterinary healthcare distribution industry is facing a significant consolidation challenge after the Federal Trade Commission (FTC), together with attorneys general from 13 states, filed a lawsuit on 13 November 2026 seeking to block the proposed US$3.5 billion acquisition of MWI Animal Health by Covetrus.

The complaint was filed in the US District Court for the Southern District of New York. It names Covetrus Inc., its private-equity owners Clayton, Dubilier & Rice (CD&R) and TPG Inc., Cencora Inc., and MWI Veterinary Supply Inc. as defendants.

The FTC alleges that Covetrus and MWI are the two largest suppliers in important segments of US veterinary distribution. Their combination, it argues, would remove a major competitive constraint, allowing the merged business to increase prices, reduce discounts and rebates, and potentially weaken service quality for veterinary practices.

The Commission voted 2–0 to authorise the legal action and seek a permanent injunction against the proposed acquisition. The 13 participating states are Arizona, Arkansas, California, Colorado, Maine, Michigan, Minnesota, Nebraska, New York, North Carolina, Ohio, Oregon and Texas.

The case is therefore likely to become an important test of how competition authorities define markets in an increasingly digital veterinary supply chain.

Understanding the transaction: How the US$3.5 billion deal was structured

Covetrus and Cencora announced their definitive agreement on 18 February 2026. The transaction valued MWI Animal Health at an enterprise value of approximately US$3.5 billion. Under the proposed structure, Cencora would receive three components of consideration:

Following completion, Cencora was expected to retain a 34.3% non-controlling common equity interest in the combined business. The transaction would therefore not have been a straightforward cash exit for Cencora. It was structured to provide immediate liquidity while preserving significant financial participation in the future performance of the combined animal-health platform.

Cencora’s strategic rationale was to refocus its portfolio on pharmaceutical distribution and related healthcare activities, while Covetrus would gain a much larger distribution footprint and a broader platform spanning companion-animal and production-animal markets. The proposed combination was positioned by the companies as an opportunity to integrate:

• Companion-animal pharmaceutical and medical-supply distribution.

• Production-animal and livestock healthcare distribution.

• Veterinary practice-management technology.

• Digital ordering and inventory-management platforms.

• Manufacturer relationships and commercial services.

• Supply-chain infrastructure and customer support.

The companies argued that a more integrated platform could improve operating efficiency, expand access to products and technology, and reduce the cost of serving veterinary practices. However, completion was conditional on regulatory approvals and other customary closing requirements.

Why the FTC is opposing the acquisition

The FTC’s case is built around a central allegation: Covetrus and MWI are not merely two large distributors operating in the same sector; they are close competitors that actively constrain each other’s pricing and commercial terms.

According to the regulator, the proposed acquisition would combine two of the most important national suppliers serving veterinary clinics and large corporate veterinary accounts.

A. Two major competitors serving the same customers

Both businesses distribute a broad portfolio of products essential to veterinary practice operations. These include:

• Veterinary pharmaceuticals and prescription medicines.

• Vaccines and biological products.

• Surgical instruments and consumables.

• Gloves, gauze, syringes and other clinical supplies.

• Diagnostic and laboratory-related products.

• Practice supplies and equipment.

• Associated distribution, ordering and customer-support services.

Their customer base extends from independent veterinary practices and single-veterinarian clinics to large corporate groups operating hundreds of locations.

The FTC argues that the national distribution infrastructure required to serve these customers is difficult for smaller competitors to replicate. Both Covetrus and MWI operate extensive distribution networks, enabling them to provide broad product availability, frequent deliveries, commercial discounts and rebates.

According to the complaint, smaller and specialist distributors do not provide an equivalent competitive alternative across the complete range of products and services required by veterinary clinics.

B. Elimination of head-to-head price competition

One of the most important elements of the FTC’s argument concerns the pricing behaviour of the two companies. The regulator alleges that Covetrus and MWI have competed aggressively for veterinary clinic accounts through:

• Direct price competition.

• Volume-based discounts.

• Pharmaceutical rebates.

• Contractual incentives.

• Service-level commitments.

• Negotiated commercial terms for large veterinary groups.

The FTC specifically identifies Covetrus’ VetSuite programme as an example of this competitive behaviour. According to the complaint, Covetrus responded to MWI’s aggressive pricing by reducing its own prices and offering rebates through VetSuite to retain or attract veterinary customers.

The regulator argues that this competitive relationship has generated meaningful savings for veterinary clinics. If MWI is absorbed into Covetrus, the FTC believes that one of the most important alternative suppliers available to clinics would disappear, weakening the incentive to compete through lower prices and better service.

C. The Vetcove marketplace: A digital platform that intensified competition

An interesting aspect of the FTC’s complaint is its treatment of Vetcove, an online veterinary purchasing marketplace. Vetcove allows veterinary practices to compare products and prices across suppliers, simplifying procurement and enabling clinics to use competing offers during negotiations.

The FTC argues that the emergence of this marketplace has actually intensified competition between Covetrus and MWI. For example, a clinic could use the price offered by one distributor to negotiate more favourable terms with the other.

Consequently, the regulator believes that eliminating one of those competitors could weaken the commercial benefits created by digital price transparency.

Covetrus rejects the FTC’s market definition

Covetrus responded to the lawsuit on 13 November, describing the FTC’s understanding of the veterinary distribution market as “narrow and outdated.” The company argues that veterinary clinics no longer depend on a small number of traditional national distributors to procure their products. Instead, it identifies three broad purchasing channels.

A. Direct purchasing from manufacturers – Covetrus argues that many veterinary pharmaceutical and animal-health manufacturers sell directly to veterinary practices.

Some manufacturers, it says, maintain sales teams that are larger than those of individual distributors. The company also states that its internal data show that nearly all veterinary practices purchase directly from suppliers.

If clinics can procure a meaningful proportion of their products directly from manufacturers, Covetrus argues, the competitive influence of a combined distributor would be more limited than the FTC suggests.

B. National and regional distributors – Covetrus also points to competition from other national and regional distributors. These businesses serve independent veterinary practices, corporate veterinary groups and other animal-health customers. The company argues that clinics regularly split their procurement between suppliers, allowing them to negotiate pricing and select products from different sources.

C. Online veterinary marketplaces – The most significant quantitative argument in Covetrus’ response concerns digital marketplaces. The company states that:

• More than 60% of US veterinary practices use online veterinary marketplaces.

• These platforms provide access to more than 40 distributors.

• They connect practices with thousands of manufacturers.

• Clinics can compare prices, access rebates and place orders through unified purchasing interfaces.

Covetrus argues that these platforms have transformed purchasing behaviour and substantially increased the number of suppliers available to veterinary clinics. It also notes that clinics frequently place multiple orders each week, purchase the same products from different suppliers and negotiate directly with manufacturers.

The company therefore maintains that the proposed merger would not eliminate the broad competitive environment in which veterinary practices currently operate. The key question for the court will be whether these alternatives are sufficiently interchangeable and competitive to constrain the merged business.

Why market definition is central to the legal battle

The disagreement between the FTC and Covetrus is fundamentally an antitrust market-definition dispute. A competition authority does not simply count every company that sells a veterinary product. It examines which suppliers genuinely constrain the pricing and commercial behaviour of the businesses involved.

For example, a manufacturer selling vaccines directly to clinics may compete with a distributor for certain products. However, that manufacturer may not offer the complete portfolio of medicines, surgical consumables, equipment, inventory services and delivery capabilities that a large veterinary practice requires.

Similarly, a digital marketplace may make price comparison easier without itself holding inventory, financing stock, operating warehouses or guaranteeing deliveries.

The distinction between access to alternative suppliers and effective competitive substitution is likely to be central to the proceedings.

The FTC is effectively arguing that the relevant competition occurs in the supply of broad veterinary distribution services, particularly for national clinic networks and large corporate accounts.

Covetrus is arguing that the modern purchasing environment is much broader and includes direct manufacturer sales, regional distributors, specialist suppliers, online marketplaces and retail channels.

The court will need to examine evidence on actual purchasing behaviour, customer switching, pricing, product coverage, distribution economics and the ability of alternative suppliers to expand.

Why corporate veterinary groups are especially important

The economics of veterinary distribution are different for a single-clinic practice and a corporate veterinary group operating across multiple states.

Large veterinary groups can aggregate purchasing volumes across dozens or hundreds of clinics. This creates significant negotiating leverage. The New York Attorney General’s announcement highlights that corporate practice groups may purchase approximately 65%–90% of their supplies from a single distributor.

This concentration of purchasing creates an important commercial relationship:

1. The veterinary group consolidates procurement across its clinics.

2. The distributor receives a large and relatively predictable volume of orders.

3. The group negotiates volume-based pricing, rebates and service commitments.

4. The distributor benefits from a large customer contract.

5. The veterinary group may pass some of the purchasing savings to pet owners through more competitive treatment pricing.

The state coalition argues that combining Covetrus and MWI would substantially weaken the ability of large veterinary groups to negotiate against two competing national suppliers. The coalition further alleges that the merged business could control more than 50% of the relevant veterinary clinic distribution markets.

That figure is an allegation advanced by the state enforcers in their relevant market analysis, not a final judicial finding or a universally applicable share across every animal-health product category.

What does the lawsuit mean for veterinary clinics and pet owners?

The potential impact extends well beyond the two companies.

Independent veterinary practices – Independent clinics often lack the purchasing scale of corporate veterinary groups. They may depend on national distributors for a broad portfolio of products, frequent replenishment and credit or rebate arrangements.

If competition between major distributors weakens, independent clinics could face reduced negotiating leverage. The effect would depend on the availability of alternative distributors, the proportion of purchases made directly from manufacturers and the commercial terms offered after any transaction.

Corporate veterinary groups – Large groups may have greater bargaining power, but they also rely on distributors capable of supplying multiple clinics across large geographic areas. The loss of an independent national supplier could make multi-site procurement contracts more difficult to negotiate.

Pet owners –  Veterinary distributors do not usually determine the final price of every consultation or procedure. However, procurement costs are one component of veterinary practice operating expenses. If clinics face higher acquisition costs for medicines, vaccines and supplies, some of those increases could eventually be reflected in client bills.

The FTC and state attorneys general argue that the transaction could therefore increase the cost of veterinary care. That outcome is not automatic: the extent of any price pass-through would depend on clinic competition, pricing policies, product availability and the ability to source alternatives.

Livestock producers – MWI also serves production-animal and livestock healthcare markets. The transaction’s implications therefore extend beyond companion animals. Veterinary distribution plays an important role in supplying livestock producers and veterinary professionals with vaccines, pharmaceuticals, biological products and other animal-health inputs.

Any change in distribution economics could affect procurement costs, product access and service arrangements for production-animal customers. However, the FTC’s public case summary places particular emphasis on veterinary clinic distribution and large corporate accounts. The precise implications for individual livestock product categories should not be assumed to be identical.

Conclusion: A defining test for veterinary distribution consolidation

The FTC’s action against the proposed Covetrus–MWI merger is a significant development for the global animal-health industry.

At stake is a US$3.5 billion transaction that would combine two major veterinary distribution businesses and potentially reshape how veterinary clinics procure medicines, vaccines, surgical supplies and other essential products.

The regulator’s case centres on the loss of direct competition, particularly in pricing, rebates, corporate contracts and service quality. Covetrus counters that the market has evolved through direct manufacturer sales, regional distributors and digital marketplaces that give veterinary practices substantially more choice.

Both positions raise important questions about the economics of modern veterinary distribution. The litigation will test whether digital purchasing platforms and alternative suppliers provide sufficient competitive discipline—or whether the national infrastructure and commercial scale of Covetrus and MWI make them uniquely important competitors.

For animal-health manufacturers, distributors, veterinary groups and investors, the case deserves close attention. It could influence not only the future of MWI and Covetrus but also how regulators evaluate consolidation across the broader veterinary healthcare ecosystem.